WO2018078442A3 - Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications - Google Patents

Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications Download PDF

Info

Publication number
WO2018078442A3
WO2018078442A3 PCT/IB2017/001427 IB2017001427W WO2018078442A3 WO 2018078442 A3 WO2018078442 A3 WO 2018078442A3 IB 2017001427 W IB2017001427 W IB 2017001427W WO 2018078442 A3 WO2018078442 A3 WO 2018078442A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
compositions
methods
dosing regimens
related indications
Prior art date
Application number
PCT/IB2017/001427
Other languages
French (fr)
Other versions
WO2018078442A2 (en
Inventor
Cristina De Min
Walter Ferlin
Fabrizio DE BENEDETTI
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2017352033A priority Critical patent/AU2017352033A1/en
Priority to SG11201903659WA priority patent/SG11201903659WA/en
Priority to CA3041434A priority patent/CA3041434A1/en
Priority to BR112019008156A priority patent/BR112019008156A2/en
Priority to JP2019521706A priority patent/JP2019532970A/en
Priority to MX2019004766A priority patent/MX2019004766A/en
Priority to EP17829009.4A priority patent/EP3528845A2/en
Priority to EA201990930A priority patent/EA201990930A1/en
Application filed by Novimmune Sa filed Critical Novimmune Sa
Priority to CN201780080221.6A priority patent/CN110167593A/en
Priority to KR1020197014837A priority patent/KR20190071785A/en
Publication of WO2018078442A2 publication Critical patent/WO2018078442A2/en
Publication of WO2018078442A3 publication Critical patent/WO2018078442A3/en
Priority to IL266174A priority patent/IL266174A/en
Priority to JP2022173528A priority patent/JP2022187025A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-γ levels.
PCT/IB2017/001427 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications WO2018078442A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP17829009.4A EP3528845A2 (en) 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
CA3041434A CA3041434A1 (en) 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
BR112019008156A BR112019008156A2 (en) 2016-10-24 2017-10-24 methods, compositions and dosage regimens in the treatment or prevention of interferon-gamma related indications
JP2019521706A JP2019532970A (en) 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing indications related to interferon gamma
MX2019004766A MX2019004766A (en) 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications.
AU2017352033A AU2017352033A1 (en) 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
EA201990930A EA201990930A1 (en) 2016-10-24 2017-10-24 METHODS, COMPOSITIONS AND DOSAGE MODES FOR TREATMENT OR PREVENTION OF INTERFERON-GAMMA DISEASES
SG11201903659WA SG11201903659WA (en) 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
CN201780080221.6A CN110167593A (en) 2016-10-24 2017-10-24 For treating or preventing method, composition and the dosage regimen of interferon-γ correlation indication
KR1020197014837A KR20190071785A (en) 2016-10-24 2017-10-24 Methods, compositions and dosage regimens for the treatment or prevention of interferon gamma related indications
IL266174A IL266174A (en) 2016-10-24 2019-04-22 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
JP2022173528A JP2022187025A (en) 2016-10-24 2022-10-28 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662411783P 2016-10-24 2016-10-24
US62/411,783 2016-10-24

Publications (2)

Publication Number Publication Date
WO2018078442A2 WO2018078442A2 (en) 2018-05-03
WO2018078442A3 true WO2018078442A3 (en) 2018-08-23

Family

ID=60957345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/001427 WO2018078442A2 (en) 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Country Status (12)

Country Link
EP (1) EP3528845A2 (en)
JP (2) JP2019532970A (en)
KR (1) KR20190071785A (en)
CN (1) CN110167593A (en)
AU (1) AU2017352033A1 (en)
BR (1) BR112019008156A2 (en)
CA (1) CA3041434A1 (en)
EA (1) EA201990930A1 (en)
IL (1) IL266174A (en)
MX (1) MX2019004766A (en)
SG (1) SG11201903659WA (en)
WO (1) WO2018078442A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884459B (en) * 2016-04-26 2024-04-02 科济生物医药（上海）有限公司 Method for improving immune response cell function
WO2021185832A1 (en) 2020-03-16 2021-09-23 Swedish Orphan Biovitrum Ag New therapeutic treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109191A2 (en) * 2005-01-27 2006-10-19 Novimmune S.A. Human anti-interferon gamma antibodies and methods of use thereof
WO2016177913A1 (en) * 2015-05-07 2016-11-10 Novimmune Sa Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP2791168A1 (en) * 2011-11-23 2014-10-22 Amgen Inc. Methods of treatment using an antibody against interferon gamma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109191A2 (en) * 2005-01-27 2006-10-19 Novimmune S.A. Human anti-interferon gamma antibodies and methods of use thereof
WO2016177913A1 (en) * 2015-05-07 2016-11-10 Novimmune Sa Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "NCT01818492 on 2015_03_08: ClinicalTrials.gov Archive", 8 March 2015 (2015-03-08), XP055288703, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT01818492/2015_03_08> [retrieved on 20160714] *
ANONYMOUS: "Public summary of opinion on orphan designation Recombinant human anti-interferon gamma monoclonal antibody for the treatment of haemophagocytic lymphohistiocytosis", EMA/COMP/164768/2010, 10 June 2010 (2010-06-10), XP055288704, Retrieved from the Internet <URL:http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2010/06/WC500094019.pdf> [retrieved on 20160714] *
M. B. JORDAN ET AL: "How I treat hemophagocytic lymphohistiocytosis", BLOOD, vol. 118, no. 15, 13 October 2011 (2011-10-13), US, pages 4041 - 4052, XP055288710, ISSN: 0006-4971, DOI: 10.1182/blood-2011-03-278127 *

Also Published As

Publication number Publication date
EP3528845A2 (en) 2019-08-28
AU2017352033A1 (en) 2019-06-06
MX2019004766A (en) 2019-09-27
JP2022187025A (en) 2022-12-15
EA201990930A1 (en) 2019-11-29
WO2018078442A2 (en) 2018-05-03
KR20190071785A (en) 2019-06-24
CA3041434A1 (en) 2018-05-03
IL266174A (en) 2019-06-30
CN110167593A (en) 2019-08-23
JP2019532970A (en) 2019-11-14
SG11201903659WA (en) 2019-05-30
BR112019008156A2 (en) 2019-07-02

Similar Documents

Publication Publication Date Title
MX2019003938A (en) Spirocyclic compounds.
MX2018003472A (en) Modulators of kras expression.
IL253727A0 (en) Purified cbd and cbda, and methods, compositions and products employing cbd or cbda
MX2022002697A (en) Allulose syrups.
TW201613966A (en) SynTac polypeptides and uses thereof
PH12018502020A1 (en) Methods for treating and preventing c. difficile infection
MX2018000715A (en) Methods for treating cancer using apilimod.
EP3164125B8 (en) Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes
MX2017012553A (en) Spirocyclic compounds.
TN2017000435A1 (en) [bis(trihydrocarbylsilyl)aminosilyl]-functionalized styrene and a method for its preparation
MY190747A (en) Method for producing silazane-siloxane copolymers and the use of such copolymers
MX2018008732A (en) Inhibition of allergic reaction using an il-33 inhibitor.
WO2017035176A8 (en) Method of preventing or treating obesity with an emc10 inhibitor
MY194227A (en) Modulators of pcsk9 expression
GB2576614B (en) Compositions, uses and methods
MX2015008310A (en) Method of treatment of hypoxia inducible factor (hif)-related conditions.
GB201901099D0 (en) Methods, uses and compositions
MX2017014436A (en) Bicyclic compounds.
GB201804163D0 (en) Uses, compositions and methods
WO2018078442A3 (en) Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
PH12019500479A1 (en) Compositions for treating dementia
IL283166A (en) Compounds that selectively and effectively inhibit hakai-mediated ubiquitination, as anti-cancer drugs
NZ747261A (en) Stevia-containing beverage
MX2017006807A (en) Titled extracts of cynara scolymus and uses thereof.
MX2017002167A (en) High performance anti-block treatments for viscoelastic solids.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17829009

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3041434

Country of ref document: CA

Ref document number: 2019521706

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019008156

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20197014837

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017829009

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017352033

Country of ref document: AU

Date of ref document: 20171024

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112019008156

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190422